We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ovascience Inc. (delisted) | NASDAQ:OVAS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.693 | 0.65 | 0.77 | 0 | 01:00:00 |
|
(Mark One)
|
|
|
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
45-1472564
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
9 4th Avenue
|
|
|
Waltham, Massachusetts
|
|
02451
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Large accelerated filer
o
|
|
Accelerated filer
x
|
|
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
x
|
Emerging Growth Company
o
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
As of September 30,
|
|
As of December 31,
|
||||
|
2018
|
|
2017
|
||||
Assets
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
|
$
|
31,917
|
|
|
$
|
15,703
|
|
Short-term investments
|
14,433
|
|
|
51,500
|
|
||
Short-term restricted cash
|
789
|
|
|
—
|
|
||
Prepaid expenses and other current assets
|
1,847
|
|
|
1,578
|
|
||
Total current assets
|
48,986
|
|
|
68,781
|
|
||
Property and equipment, net
|
108
|
|
|
3,113
|
|
||
Investment in joint venture
|
140
|
|
|
146
|
|
||
Long-term restricted cash
|
—
|
|
|
789
|
|
||
Other long-term assets
|
—
|
|
|
24
|
|
||
Total assets
|
$
|
49,234
|
|
|
$
|
72,853
|
|
Liabilities and stockholders’ equity
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable
|
$
|
604
|
|
|
$
|
2,242
|
|
Accrued expenses and other current liabilities
|
3,277
|
|
|
5,562
|
|
||
Total current liabilities
|
3,881
|
|
|
7,804
|
|
||
Other non-current liabilities
|
442
|
|
|
751
|
|
||
Total liabilities
|
4,323
|
|
|
8,555
|
|
||
Commitments and contingencies (Note 10)
|
|
|
|
|
|
||
Stockholders’ equity:
|
|
|
|
|
|
||
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding
|
—
|
|
|
—
|
|
||
Common stock, $0.001 par value; 100,000,000 shares authorized; 35,826,429 and 35,725,230 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
|
36
|
|
|
36
|
|
||
Additional paid-in capital
|
367,110
|
|
|
365,769
|
|
||
Accumulated other comprehensive loss
|
(3
|
)
|
|
(27
|
)
|
||
Accumulated deficit
|
(322,232
|
)
|
|
(301,480
|
)
|
||
Total stockholders’ equity
|
44,911
|
|
|
64,298
|
|
||
Total liabilities and stockholders’ equity
|
$
|
49,234
|
|
|
$
|
72,853
|
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
||||||||||||
|
2018
|
|
2017
|
|
2018
|
|
2017
|
||||||||
Revenues
|
$
|
55
|
|
|
$
|
56
|
|
|
$
|
203
|
|
|
$
|
204
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Costs of revenues
|
44
|
|
|
29
|
|
|
210
|
|
|
572
|
|
||||
Research and development
|
1,680
|
|
|
4,016
|
|
|
6,695
|
|
|
14,777
|
|
||||
Selling, general and administrative
|
4,176
|
|
|
5,056
|
|
|
11,045
|
|
|
22,935
|
|
||||
Restructuring
|
53
|
|
|
361
|
|
|
3,637
|
|
|
3,842
|
|
||||
Total costs and expenses
|
5,953
|
|
|
9,462
|
|
|
21,587
|
|
|
42,126
|
|
||||
Loss from operations
|
(5,898
|
)
|
|
(9,406
|
)
|
|
(21,384
|
)
|
|
(41,922
|
)
|
||||
Interest income, net
|
228
|
|
|
193
|
|
|
643
|
|
|
560
|
|
||||
Other income (expense), net
|
(7
|
)
|
|
(3
|
)
|
|
(5
|
)
|
|
(37
|
)
|
||||
Loss from equity method investment
|
(2
|
)
|
|
(140
|
)
|
|
(6
|
)
|
|
(1,015
|
)
|
||||
Loss before income taxes
|
(5,679
|
)
|
|
(9,356
|
)
|
|
(20,752
|
)
|
|
(42,414
|
)
|
||||
Income tax expense
|
—
|
|
|
11
|
|
|
—
|
|
|
33
|
|
||||
Net loss
|
$
|
(5,679
|
)
|
|
$
|
(9,367
|
)
|
|
$
|
(20,752
|
)
|
|
$
|
(42,447
|
)
|
Net loss per share—basic and diluted
|
$
|
(0.16
|
)
|
|
$
|
(0.26
|
)
|
|
$
|
(0.58
|
)
|
|
$
|
(1.19
|
)
|
Weighted average number of shares used in net loss per share—basic and diluted
|
35,790
|
|
|
35,687
|
|
|
35,759
|
|
|
35,664
|
|
||||
Net loss
|
$
|
(5,679
|
)
|
|
$
|
(9,367
|
)
|
|
$
|
(20,752
|
)
|
|
$
|
(42,447
|
)
|
Other comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized gains on available-for-sale securities
|
5
|
|
|
27
|
|
|
24
|
|
|
38
|
|
||||
Comprehensive loss
|
$
|
(5,674
|
)
|
|
$
|
(9,340
|
)
|
|
$
|
(20,728
|
)
|
|
$
|
(42,409
|
)
|
|
|
Nine Months Ended
September 30, |
||||||
|
2018
|
|
2017
|
||||
Cash flows from operating activities:
|
|
|
|
|
|
||
Net loss
|
$
|
(20,752
|
)
|
|
(42,447
|
)
|
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
||
Depreciation and amortization
|
633
|
|
|
1,311
|
|
||
Impairment of property and equipment related to restructuring
|
2,203
|
|
|
250
|
|
||
Gain on sale of property, plant and equipment
|
(66
|
)
|
|
—
|
|
||
Amortization of (discount) premium on debt securities
|
(176
|
)
|
|
101
|
|
||
Stock-based compensation expense
|
1,259
|
|
|
6,377
|
|
||
Issuance of common stock for director fees
|
82
|
|
|
102
|
|
||
Net loss on equity method investment
|
6
|
|
|
1,015
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
||
Prepaid expenses and other assets
|
(473
|
)
|
|
635
|
|
||
Other assets
|
24
|
|
|
—
|
|
||
Accounts payable
|
(1,638
|
)
|
|
517
|
|
||
Accrued expenses, deferred rent and other non-current liabilities
|
(2,594
|
)
|
|
(5,440
|
)
|
||
Net cash used in operating activities
|
(21,492
|
)
|
|
(37,579
|
)
|
||
Cash flows from investing activities:
|
|
|
|
|
|
||
Investment in joint venture
|
—
|
|
|
(550
|
)
|
||
Purchases of plant and equipment
|
—
|
|
|
(112
|
)
|
||
Maturities of short-term investments
|
70,759
|
|
|
67,839
|
|
||
Proceeds from sale of property, plant and equipment
|
438
|
|
|
—
|
|
||
Purchases of short-term investments
|
(33,491
|
)
|
|
(48,403
|
)
|
||
Net cash provided by investing activities
|
37,706
|
|
|
18,774
|
|
||
Cash flows from financing activities:
|
|
|
|
|
|
||
Net cash provided by financing activities
|
—
|
|
|
—
|
|
||
Net increase (decrease) in cash, cash equivalents and restricted cash
|
16,214
|
|
|
(18,805
|
)
|
||
Cash, cash equivalents and restricted cash at beginning of period
|
16,492
|
|
|
44,369
|
|
||
Cash, cash equivalents and restricted cash at end of period
|
$
|
32,706
|
|
|
$
|
25,564
|
|
|
As of September 30,
|
|
As of September 30,
|
||||
|
2018
|
|
2017
|
||||
Cash and cash equivalents
|
$
|
31,917
|
|
|
$
|
24,775
|
|
Restricted cash
|
789
|
|
|
789
|
|
||
Total cash, cash equivalents and restricted cash
|
$
|
32,706
|
|
|
$
|
25,564
|
|
|
|
|
As of September 30,
|
||||
|
2018
|
|
2017
|
||
Outstanding stock options and restricted stock units
|
5,160
|
|
|
6,468
|
|
|
|
•
|
Level 1—quoted prices (unadjusted) in active markets for identical assets.
|
•
|
Level 2—quoted prices for similar assets in active markets or inputs that are observable for the asset, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
|
•
|
Level 3—unobservable inputs based on our assumptions used to measure assets at fair value.
|
Description
|
|
Balance as of September 30, 2018
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and money market funds
|
|
$
|
31,917
|
|
|
$
|
31,917
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Corporate debt securities (including commercial paper)
|
|
8,968
|
|
|
—
|
|
|
8,968
|
|
|
—
|
|
||||
U.S. government securities
|
|
5,465
|
|
|
—
|
|
|
5,465
|
|
|
—
|
|
||||
Total
|
|
$
|
46,350
|
|
|
$
|
31,917
|
|
|
$
|
14,433
|
|
|
$
|
—
|
|
Description
|
|
Balance as of
December 31, 2017 |
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and money market funds
|
|
$
|
15,703
|
|
|
$
|
15,703
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Corporate debt securities (including commercial paper)
|
|
35,531
|
|
|
—
|
|
|
35,531
|
|
|
—
|
|
||||
U.S. government securities
|
|
15,969
|
|
|
—
|
|
|
15,969
|
|
|
—
|
|
||||
Total
|
|
$
|
67,203
|
|
|
$
|
15,703
|
|
|
$
|
51,500
|
|
|
$
|
—
|
|
|
September 30, 2018
|
|
Amortized Cost
|
|
Gross Unrealized
Gains
|
|
Gross Unrealized
Losses
|
|
Fair Value
|
||||||||
Cash and money market funds
|
|
$
|
31,917
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
31,917
|
|
Corporate debt
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Due in one year or less
|
|
8,969
|
|
|
—
|
|
|
(1
|
)
|
|
8,968
|
|
||||
U.S. government securities
|
|
|
|
|
|
|
|
|
||||||||
Due in one year or less
|
|
5,467
|
|
|
—
|
|
|
(2
|
)
|
|
5,465
|
|
||||
Total
|
|
$
|
46,353
|
|
|
$
|
—
|
|
|
$
|
(3
|
)
|
|
$
|
46,350
|
|
Reported as:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and cash equivalents
|
|
$
|
31,917
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
31,917
|
|
Short-term investments
|
|
14,436
|
|
|
—
|
|
|
(3
|
)
|
|
14,433
|
|
||||
Total
|
|
$
|
46,353
|
|
|
$
|
—
|
|
|
$
|
(3
|
)
|
|
$
|
46,350
|
|
December 31, 2017
|
|
Amortized Cost
|
|
Gross Unrealized
Gains
|
|
Gross Unrealized
Losses
|
|
Fair Value
|
||||||||
Cash and money market funds
|
|
$
|
15,703
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
15,703
|
|
Corporate debt
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Due in one year or less
|
|
38,053
|
|
|
—
|
|
|
(21
|
)
|
|
38,032
|
|
||||
U.S. government securities
|
|
|
|
|
|
|
|
|
||||||||
Due in one year or less
|
|
13,474
|
|
|
—
|
|
|
(6
|
)
|
|
13,468
|
|
||||
Total
|
|
$
|
67,230
|
|
|
$
|
—
|
|
|
$
|
(27
|
)
|
|
$
|
67,203
|
|
Reported as:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and cash equivalents
|
|
$
|
15,703
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
15,703
|
|
Short-term investments
|
|
51,527
|
|
|
—
|
|
|
(27
|
)
|
|
51,500
|
|
||||
Total
|
|
$
|
67,230
|
|
|
$
|
—
|
|
|
$
|
(27
|
)
|
|
$
|
67,203
|
|
|
|
As of September 30,
|
|
As of December 31,
|
||||
|
2018
|
|
2017
|
||||
Laboratory equipment
|
$
|
1,247
|
|
|
$
|
3,480
|
|
Furniture
|
230
|
|
|
371
|
|
||
Computer equipment
|
13
|
|
|
208
|
|
||
Leasehold improvements
|
288
|
|
|
2,754
|
|
||
Total property and equipment, gross
|
1,778
|
|
|
6,813
|
|
||
Less: accumulated depreciation and amortization
|
(1,670
|
)
|
|
(3,700
|
)
|
||
Total property and equipment, net
|
$
|
108
|
|
|
$
|
3,113
|
|
|
As of September 30,
|
|
As of December 31,
|
||||
|
2018
|
|
2017
|
||||
Compensation and related benefits, including severance
|
$
|
1,447
|
|
|
$
|
2,215
|
|
Development, site costs and contract manufacturing
|
—
|
|
|
519
|
|
||
Legal, audit and tax services
|
422
|
|
|
1,542
|
|
||
Consulting
|
142
|
|
|
160
|
|
||
Deferred rent
|
353
|
|
|
334
|
|
||
Other accrued expenses and other current liabilities
|
913
|
|
|
792
|
|
||
|
$
|
3,277
|
|
|
$
|
5,562
|
|
|
|
Shares
|
|
Weighted
average
exercise
price per
share
|
|
Weighted
average
remaining
contractual
term
(years)
|
|
Aggregate
intrinsic
value
(in thousands)
|
|||||
Outstanding at December 31, 2017
|
5,745,815
|
|
|
$
|
7.28
|
|
|
8.32
|
|
$
|
43
|
|
Granted
|
1,251,877
|
|
|
0.96
|
|
|
|
|
|
|
||
Forfeited/Canceled
|
(1,837,518
|
)
|
|
5.87
|
|
|
|
|
|
|
||
Outstanding at September 30, 2018
|
5,160,174
|
|
|
6.23
|
|
|
7.80
|
|
1
|
|
||
Exercisable at September 30, 2018
|
2,577,812
|
|
|
10.61
|
|
|
6.76
|
|
1
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||
|
2018
|
|
2017
|
|
2018
|
|
2017
|
Risk-free interest rate
|
2.7%
|
|
1.9%
|
|
2.7%
|
|
1.3% - 2.2%
|
Dividend yield
|
—
|
|
—
|
|
—
|
|
—
|
Volatility
|
83%
|
|
92%
|
|
83% - 85%
|
|
89% - 109%
|
Expected term (years)
|
5.3
|
|
6.1
|
|
5.3 - 6.1
|
|
2.0 - 6.9
|
|
Accrued restructuring balance as of December 31, 2017
|
|
$
|
403
|
|
Plus:
|
|
|
||
Severance
|
|
1,377
|
|
|
Other
|
|
109
|
|
|
Less:
|
|
|
||
Payments
|
|
(1,842
|
)
|
|
Accrued restructuring balance as of September 30, 2018
|
|
$
|
47
|
|
|
|
|
|
|
|
Three Months Ended,
|
|
2018/ 2017
Comparison
|
|
Nine Months Ended
|
|
2018 / 2017
Comparison |
||||||||||||||||||||||
|
September 30,
|
|
Increase / (Decrease)
|
|
September 30,
|
|
Increase / (Decrease)
|
||||||||||||||||||||||
|
2018
|
|
2017
|
|
$
|
|
%
|
|
2018
|
|
2017
|
|
$
|
|
%
|
||||||||||||||
Revenues
|
$
|
55
|
|
|
$
|
56
|
|
|
$
|
(1
|
)
|
|
(2
|
)%
|
|
$
|
203
|
|
|
$
|
204
|
|
|
$
|
(1
|
)
|
|
—
|
%
|
Costs of revenues
|
44
|
|
|
29
|
|
|
15
|
|
|
52
|
%
|
|
210
|
|
|
572
|
|
|
(362
|
)
|
|
(63
|
)%
|
||||||
Research and development expenses
|
1,680
|
|
|
4,016
|
|
|
(2,336
|
)
|
|
(58
|
)%
|
|
6,695
|
|
|
14,777
|
|
|
(8,082
|
)
|
|
(55
|
)%
|
||||||
Selling, general and administrative expenses
|
4,176
|
|
|
5,056
|
|
|
(880
|
)
|
|
(17
|
)%
|
|
11,045
|
|
|
22,935
|
|
|
(11,890
|
)
|
|
(52
|
)%
|
||||||
Restructuring
|
53
|
|
|
361
|
|
|
(308
|
)
|
|
(85
|
)%
|
|
3,637
|
|
|
3,842
|
|
|
(205
|
)
|
|
(5
|
)%
|
||||||
Interest income, net
|
228
|
|
|
193
|
|
|
35
|
|
|
18
|
%
|
|
643
|
|
|
560
|
|
|
83
|
|
|
15
|
%
|
||||||
Other income (expense), net
|
(7
|
)
|
|
(3
|
)
|
|
4
|
|
|
133
|
%
|
|
(5
|
)
|
|
(37
|
)
|
|
(32
|
)
|
|
(86
|
)%
|
||||||
Loss from equity method investment
|
2
|
|
|
140
|
|
|
(138
|
)
|
|
(99
|
)%
|
|
6
|
|
|
1,015
|
|
|
(1,009
|
)
|
|
(99
|
)%
|
||||||
Income tax expense
|
—
|
|
|
11
|
|
|
(11
|
)
|
|
(100
|
)%
|
|
—
|
|
|
33
|
|
|
(33
|
)
|
|
(100
|
)%
|
||||||
Net loss
|
$
|
5,679
|
|
|
$
|
9,367
|
|
|
$
|
(3,688
|
)
|
|
(39
|
)%
|
|
$
|
20,752
|
|
|
$
|
42,447
|
|
|
$
|
(21,695
|
)
|
|
(51
|
)%
|
|
•
|
a $1.3 million decrease in employee compensation, including stock-based compensation, as a result of our corporate restructuring activities;
|
•
|
a $0.1 million decrease in travel, facilities and other costs primarily attributable to the decrease in our headcount as result of our corporate restructuring initiatives; and
|
•
|
a $0.9 million decrease in marketing, professional and commercial related costs primarily attributable to our shift in corporate strategy to focus on research and development activities.
|
•
|
a $4.9 million decrease in employee compensation, including stock-based compensation, as a result of our corporate restructuring activities;
|
•
|
a $1.7 million decrease in travel, facilities and other costs primarily attributable to the decrease in our headcount as result of our corporate restructuring initiatives; and
|
•
|
a $1.5 million decrease in research and consulting costs primarily attributable to the decrease in our headcount and our corporate restructuring activities.
|
•
|
the nature, timing and estimated costs of the efforts necessary to complete the development of our treatments;
|
•
|
the anticipated completion dates of our treatment development efforts, if any; or
|
•
|
the period in which material net cash in-flows are expected to commence, if at all, from our current treatments and any potential future treatments.
|
•
|
a $1.1 million decrease in employee compensation, including stock-based compensation, a result of our corporate restructuring activities;
|
|
•
|
a $0.3 million decrease in marketing and commercial related activities primarily attributable to our shift in corporate strategy to focus on research and development activities; and
|
•
|
a $0.5 million increase in in legal and professional costs primarily attributable to the settlement of ongoing litigation.
|
•
|
a $8.7 million decrease in employee compensation, including stock-based compensation, a result of our corporate restructuring activities;
|
•
|
a $1.2 million decrease in marketing and commercial related activities primarily attributable to our shift in corporate strategy to focus on research and development activities; and
|
•
|
a $2.0 million decrease in travel, facilities and other costs primarily attributable to the decrease in our headcount as result of our corporate restructuring initiatives.
|
|
|
September 30,
|
|
December 31,
|
||||
|
2018
|
|
2017
|
||||
Cash, cash equivalents and short-term investments
|
$
|
46,350
|
|
|
$
|
67,203
|
|
Working capital
|
45,105
|
|
|
60,977
|
|
|
Nine Months Ended September 30,
|
||||||
|
2018
|
|
2017
|
||||
Cash (used in) provided by:
|
|
|
|
|
|
||
Operating activities
|
$
|
(21,492
|
)
|
|
$
|
(37,579
|
)
|
Investing activities
|
37,706
|
|
|
18,774
|
|
||
Capital expenditures (included in investing activities above)
|
—
|
|
|
(112
|
)
|
||
Financing activities
|
—
|
|
|
—
|
|
|
•
|
the costs associated with clinical studies and trials;
|
•
|
the costs involved in collaborating with our academic and commercial partners, and any contract research organizations;
|
•
|
preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
|
•
|
establishing collaborations and partnerships on favorable terms, if at all;
|
•
|
developing, acquiring or in-licensing other potential fertility treatments and technologies; and
|
•
|
the timing for completion of our transaction with Millendo.
|
|
|
|
|
|
|
Exhibit
|
|
Description
|
|
|
|
2.1
|
|
Agreement and Plan of Merger and Reorganization, dated as of August 8, 2018, by and among OvaScience, Merger Sub and Millendo
(incorporated by reference from Exhibit 2.1 to the Current Report on Form 8-K filed on August 9, 2018, File No. 00135890).
|
|
|
|
2.2
|
|
|
|
|
|
2.3
|
|
Second Amendment to Agreement and Plan of Merger and Reorganization, dated as of August 8, 2018, by and among OvaScience, Inc., Orion Merger Sub, Inc. and Millendo Therapeutics, Inc., dated as of November 1, 2018 (
incorporated by reference from Exhibit 2.1 to the Current Report on Form 8-K filed on November 1, 2018, File No. 00135890
).
|
|
|
|
2.4
|
|
Form of OvaScience Voting Agreement, by and between Millendo and certain stockholders of OvaScience
(incorporated by reference from Exhibit 2.2 to the Current Report on Form 8-K filed on August 9, 2018, File No. 00135890).
|
|
|
|
2.5
|
|
Form of Millendo Voting Agreement , by and between OvaScience, certain stockholders of Millendo and solely for purposes of Section 1.4 thereof, Millendo
(incorporated by reference from Exhibit 2.3 to the Current Report on Form 8-K filed on August 9, 2018, File No. 00135890).
|
|
|
|
2.6
|
|
Form of Lock-Up Agreement, by and between OvaScience, Millendo and certain stockholders of OvaScience and Millendo
(incorporated by reference from Exhibit 2.4 to the Current Report on Form 8-K filed on August 9, 2018, File No. 00135890).
|
|
|
|
3.1
|
|
Bylaws of OvaScience, as amended August 8, 2018
(incorporated by reference from Exhibit 3.1 to the Current Report on Form 8-K filed on August 9, 2018, File No. 00135890).
|
|
|
|
10.1#
|
|
Amendment to Retention Agreement between OvaScience and Jonathan Gillis, dated August 8, 2018
(incorporated by reference from Exhibit 10.1 to the Current Report on Form 8-K filed on August 9, 2018, File No. 00135890).
|
|
|
|
10.2
|
|
Stock Purchase Agreement, by and among OvaScience, Inc., the purchasers set forth on Schedule I thereto and Millendo Therapeutics, Inc., dated as of November 1, 2018 (
incorporated by reference from Exhibit 10.1 to the Current Report on Form 8-K filed on November 1, 2018, File No. 00135890
).
|
|
|
|
10.3
|
|
Registration Rights Agreement, by and among OvaScience, Inc. and the persons listed on Schedule A thereto, dated as of November 1, 2018 (
incorporated by reference from Exhibit 10.2 to the Current Report on Form 8-K filed on November 1, 2018, File No. 00135890
).
|
|
|
|
31.1
|
|
|
|
|
|
31.2
|
|
|
|
|
|
32.1
|
|
|
|
|
|
32.2
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Presentation Linkbase Document
|
|
|
|
|
OVASCIENCE, INC.
|
||
|
|
|
||
|
|
By:
|
/s/ Christopher Kroeger
|
|
|
|
|
Name:
|
Christopher Kroeger, M.D., M.B.A.
|
Date:
|
November 9, 2018
|
|
Title:
|
Chief Executive Officer (Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Jonathan Gillis
|
|
|
|
|
Name:
|
Jonathan Gillis
|
Date:
|
November 9, 2018
|
|
Title:
|
SVP, Finance (Principal Accounting and Financial Officer)
|
|
1 Year Ovascience Inc. (delisted) Chart |
1 Month Ovascience Inc. (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions